Trial Profile
Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Temelimab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms RAINBOW-T1D
- Sponsors GeNeuro Australia
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 07 May 2019 According to a GeNeuro media release, The positive effects observed in the 6-month double-blind placebo-controlled period were extended to those patients who switched to temelimab from placebo in the open-label extension period.
- 07 May 2019 Positive results presented in the GeNeuro media release.